Home Radiation MD Anderson and Empyrean Announce Agreement to Develop Novel Radiation Therapy Technologies

MD Anderson and Empyrean Announce Agreement to Develop Novel Radiation Therapy Technologies


Newswise – HOUSTON and BOCA RATON, Fla. – The University of Texas MD Anderson Cancer Center and Empyrean Medical Systems, Inc. today announced an exclusive license and joint development agreement to advance new technologies and products in the fields of radiation oncology and cancer therapy.

This agreement brings together the complementary research and development expertise of both institutions to advance MD Anderson’s innovative intellectual property to improve the delivery of radiation therapy to cancer patients.

“We are proud to partner with MD Anderson as we strive to bring these new technologies to light,” said Kal Fishman, founder, president and CEO of Empyrean Medical Systems. “Our goal is to develop several cutting-edge products to deliver optimal radiation therapy to our clinicians and make a real difference for patients and their families.”

Under this agreement, Empyrean obtains an exclusive license to develop and commercialize a new radiation therapy approach originally discovered by MD Anderson researchers. The Magnetically Optimized Very High Energy Electronic Therapy (MOVHEET) method has the potential to significantly improve the accuracy of radiation delivered by machines with a similar footprint to conventional options.

“The combined expertise of MD Anderson and Empyrean allows us to take advantage of the dosimetric characteristics of ultra-high energy electron beams for the treatment of malignant tumors,” said Mohammad Salehpour, Ph.D., professor of physics radiation to MD Anderson. “The MOVHEET system is designed from the ground up to deliver both conventional and FLASH dose rate radiation therapy with increased precision to increase its effectiveness.”

In addition to MOVHEET, Empyrean and MD Anderson intend to collaboratively develop additional technologies based on Empyrean’s intellectual property, all with the goal of optimizing cancer patient care. MD Anderson will receive an equity interest in Empyrean and is eligible to receive certain royalties and other financial consideration.

– 30 –


MD Anderson has an institutional conflict of interest with Empyrean Medical Systems due to this exclusive license and joint development agreement and implements an institutional plan to manage and monitor conflicts of interest for all research related to this OK.

About Empyrean Medical Systems, Inc.:

Empyrean Medical Systems is an innovator and paradigm shifter in radiation oncology. The company aims to fundamentally change the way cancer patients are treated around the world while improving and enhancing clinical outcomes and quality of life for every patient. As a cutting-edge innovator, Empyrean aims to disrupt the fields of oncology and radiation oncology through the introduction of cutting-edge medical devices, artificial intelligence analytical solutions, clinical applications and therapeutic agents. Empyrean’s multimodal solutions deliver personalized and efficient healthcare, improving clinical productivity and improving outcomes for patients, providers, healthcare systems and researchers worldwide. For more information, visit www.EmpyreanMed.com.

About MD Anderson

The MD Anderson Cancer Center at the University of Texas at Houston is one of the world’s most respected centers focused on cancer patient care, research, education, and prevention. The institution’s sole mission is to end cancer for patients and their families worldwide. MD Anderson is one of 53 comprehensive cancer centers designated by the National Cancer Institute (NCI). MD Anderson is #1 for cancer in US News & World Report’s “Best Hospitals” ranking. It has been named one of the top two hospitals in the nation for cancer since the rankings began in 1990. MD Anderson receives an NCI Cancer Center Support Grant from the National Institutes of Health (P30 CA016672).